Aktienanalyse zu ICON PLC (ICLR)ICLRICON PLC

ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals. It operates in the Healthcare sector (COMMERCIAL PHYSICAL AND BIOLOGICAL RESEARCH industry).

ICON PLC (ICLR) is a good buy right now due to its current price of $185.27 being close to the analyst price target of $185 from BofA, indicating potential for growth. The stock has a strong RSI of 77.185, suggesting it is in a bullish momentum phase. However, the main risk is the forward P/E ratio of 14.7493, which indicates that the stock may be overvalued if earnings do not meet expectations in the upcoming quarter.

15 analysts cover ICLR: 10 rate it Buy, 5 Hold and 0 Sell. The average price target is 202.67.